27 studies found for:    ACADIA
Show Display Options
Rank Status Study
1 Active, not recruiting A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis
Condition: Lumbar Spinal Stenosis
Interventions: Device: ACADIA® Facet Replacement System;   Device: Instrumented posterolateral fusion
2 Recruiting Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children
Conditions: Attention Deficit Hyperactivity Disorder;   Anxiety
Interventions: Dietary Supplement: L. helveticus R0052 and B. longum R0175;   Other: Placebo
3 Unknown  Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression
Conditions: Anxiety;   Depression
Interventions: Other: Probiotics;   Drug: Placebo
4 Completed Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
Condition: Schizophrenia
Intervention: Drug: ACP-103
5 Recruiting A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
Condition: Alzheimer's Disease Psychosis
Interventions: Drug: Pimavanserin tartrate;   Drug: Placebo
6 Approved for marketing Expanded Access of Pimavanserin for Patients With PD Psychosis
Condition: Parkinson's Disease Psychosis
Intervention: Drug: Pimavanserin tartrate
7 Completed An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
Condition: Parkinson's Disease Psychosis
Intervention: Drug: pimavanserin tartrate (ACP-103)
8 Completed
Has Results
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Condition: Parkinson's Disease Psychosis
Interventions: Drug: pimavanserin tartrate;   Drug: placebo
9 Completed
Has Results
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Condition: Parkinson's Disease Psychosis
Intervention: Drug: Pimavanserin tartrate (ACP-103)
10 Active, not recruiting A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Condition: Parkinson's Disease Psychosis
Intervention: Drug: pimavanserin tartrate (ACP-103)
11 Completed ACP-104 in Acutely Psychotic Subjects With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: ACP-104;   Drug: Placebo
12 Completed
Has Results
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Condition: Parkinson's Disease Psychosis
Interventions: Drug: Pimavanserin tartrate (ACP-103);   Drug: Placebo
13 Completed Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
Conditions: Hallucinations;   Psychoses;   Parkinson's Disease
Intervention: Drug: ACP-103
14 Active, not recruiting Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
Condition: Alzheimer's Disease
Interventions: Drug: T-817MA-H;   Drug: T-817MA-L;   Drug: Placebo
15 Completed A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents
Condition: Bipolar I Disorder
Intervention: Drug: Divalproex Sodium (Depakote ER)
16 Completed A Transformational Teaching Intervention: Adolescents in Motion (AIM) Trial
Condition: Physical Activity
Interventions: Behavioral: Transformational Teaching;   Behavioral: Standard Educational Practices
17 Completed
Has Results
To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)
Condition: Contraception
Interventions: Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027);   Drug: Ortho Tri Cyclen Lo
18 Completed
Has Results
A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
Condition: Acute, Uncomplicated Human Influenza
Interventions: Drug: Peramivir;   Drug: Placebo
19 Active, not recruiting The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Condition: Cardiovascular Disease
Interventions: Drug: bococizumab (PF-04950615);   Drug: Placebo
20 Recruiting The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Condition: Cardiovascular Disease
Interventions: Drug: bococizumab (PF-04950615);   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Indicates status has not been verified in more than two years